COMPANIES looking to invest in
clinical trials in Australia may be
reconsidering their options, after a
report found that the nation is the
second least competitive as a
market for clinical trial investment.
The 2012 KPMG Competitive
Alternatives report compared
business costs and other
competitiveness factors in more
than 110 cities in 14 countries, and
found that Australia is the second
most expensive country for
investing in clinical trials, behind
Japan, and that Sydney ranks 111th
out of 113 in the list of most
expensive cities, only topped by
Tokyo and Osaka.
Sydney was ...
The above snippet is the first part of an article sent to subscribers in Pharmacy Daily's issue from 21 May 12
Pharmacy Daily is Australia's favourite online publication dedicated to the pharmacy industry. The publication launched in March 2007 and is distributed every day by email to pharmacists across the country. MORE